Final-draft-SOO-RAIIC The Joint Science and Technology Office (JSTO) Defense Threat Reduction Agency (DTRA) has announced an upcoming funding opportunity for members of the Medical CBRN Defense Consortium (MCDC) to develop technologies that can accelerate the identification and immune profile of novel antigens in emerging infectious diseases (EID). JSTO intends to incorporate the final technology into […]
DTRA MCDC RAIIC Funding Opportunity Read More »
Final-Draft-SOO-IMMIR The Joint Science and Technology Office (JSTO) within the Defense Threat Reduction Agency (DTRA) has announced an upcoming funding opportunity for members of the Medical CBRN Defense Consortium (MCDC). The objective of the IMMIR solicitation is to develop innovative technologies for vaccine monitoring via a compact wearable device that can analyze minute blood samples.
DTRA Issues Draft SOO for Continual Blood Sampling Technology Read More »
Even with incredible scientific progress, cancer remains the second highest leading cause of death in the United States (U.S.) and one of the highest causes of death worldwide. To accelerate and bolster the great innovations made in therapeutics, diagnostics, and patient care, the Biden-Harris administration has reignited the Cancer Moonshot initiative. This program, introduced by
Cancer Moonshot and the ARPA-H Cancer Funding Landscape Read More »
24-08-mRNALongTerm_Final The Biomedical Advanced Research and Development Authority (BARDA) has released a Request for Project Proposals (RPP) aimed at vaccine development and response for emerging infectious diseases and rapid pandemic influenza. The RPP, numbered RRPV-24-08-mRNALongTerm, focuses on creating a lasting partnership that builds and maintains a robust mRNA preparedness and response system for pandemic influenza
August-24-Broad-Spectrum-SOO The Defense Threat Reduction Agency (DTRA) has released a Statement of Objectives (SOO) to develop prototype Medical Countermeasures (MCMs) aimed at addressing therapeutic indications of Warfigher exposure to viral and bacterial biothreat agents. Key Information and Deadlines The Project Agreement Holder must state if their proposal is for the solution of the objecties of
DTRA Issues SOO for Broad-Spectrum Therapeutics Read More »
DECIDE_ET_Solicitation_DRAFT The Advanced Research Projects Agency for Health (ARPA-H) has introduced the Decentralized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic (ET), representing a crucial initiative designed to revolutionize the production and validation of autologous cell therapies. This ET targets significant enhancements in the production processes at Academic Medical Centers (AMCs), focusing on
ARPA-H Issues Draft Solicitation for Autologous Cell Therapy (ACT) Read More »
RPP-24-02-ODM The Biomedical Advanced Research and Development Authority (BARDA) has released an essential Request for Project Proposals (RPP) aimed at the preparation for and response to public health emergencies through On-Demand Manufacturing. The RPP, numbered 24-02-ODM, focuses advancing manufacturing technologies that will improve access and enable faster, cheaper, more rapid, and flexible production of vaccines
BARDA Issues RPP for On-Demand Manufacturing Read More »
24-SOL-109+POSEIDON+DRAFT+ISO_9+AUG+24 The Advanced Research Projects Agency for Health (ARPA-H) has issued a Request for Proposals (RFP) for the POSEIDON program, a groundbreaking initiative aimed at advancing cancer screening technologies. The Platform Optimizing SynBio for Early Intervention and Detection in Oncology (POSEIDON) seeks to develop innovative, non-invasive tests that can detect multiple cancers at an early
ARPA-H Announces RFP for Cancer Intervention and Detection Read More »
Evaluation Criteria White Paper Template W911SR-24-S-HDTX+RFI The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), along with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), invites stakeholders from industry, academia, and nonprofit sectors to submit white papers for the development and repurposing of host-directed therapeutics.
JPM & JPEO Issues RFI for Host-Directed Therapeutics for Prophylaxis Read More »
BARDA RRPV 24-03-SmMol The Biomedical Advanced Research and Development Authority (BARDA) has released a Request for Project Proposals (RPP) under the Rapid Response Partnership Vehicle (RRPV) for developing small molecule therapeutics aimed at COVID-19 Pre-exposure Prophylaxis (PrEP). This initiative enhances national health security by advancing medical countermeasures against SARS-CoV-2 and future health threats. BARDA’s call
BARDA Announces Request for Project Proposals for Small Molecule Drugs Read More »
Proposers’ Day Notice 24-SOL-109+POSEIDON+DRAFT+ISO_9+AUG+24 The Advanced Research Projects Agency for Health (ARPA-H) has recently unveiled an exciting initiative named POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in ONcology). This program aims to drastically shift the current landscape of cancer detection through innovative, synthetic biology-based approaches. As part of this groundbreaking venture, ARPA-H is
ARPA-H Announces Proposers’ Day for New POSEIDON Program Read More »
BioMaP_RPP_24-05-N95 The Biomedical Advanced Research and Development Authority (BARDA) has released an essential Request for Project Proposals (RPP) aimed at sustaining the manufacturing capacity of N95 respirators, a crucial element in the biopharmaceutical and healthcare sectors, especially highlighted during the COVID-19 pandemic. The RPP, numbered 24-05-N95, focuses on maintaining a “warm-base” status of manufacturing capabilities
BARDA Issues RPP for N95 Respirator Production Read More »
